In breast cancer, colon cancer, and melanoma, inhibition of CSF-1/CSF-1R signaling using an anti-CSF-1R antibody can regulate both the number and the function of MDSCs, induce antitumor T-cell responses and tumor regression when combined with CTLA-4 blockade therapy (115). This evidence concerns the gene CSF1R and breast carcinoma.